Analysts expect Foghorn Therapeutics to report a Q3 2026 loss of $0.23 per share on revenue of $7.15 million, while the current stock price of $7.85 sits well below the average analyst target of $16.60.
Investors are primarily focused on clinical data readouts for FHD-286, the company's lead chromatin regulatory system candidate for AML. Recent developments include the advancement of FHD-909 into clinical trials through a strategic partnership with Eli Lilly, which provides significant validation for the platform.
Management's guidance on cash runway and progress with the Gene Traffic control platform will be critical for maintaining market confidence.